Creative Medical Technology Holdings, Inc. CELZ
Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) is a pain/anesthesia drug developer. Its lead program, Olastrocel (CELZ-201, ADAPT trial), is in Phase 1 for chronic lower back pain due to degenerative disc disease.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Olastrocel (CELZ-201 DDT, ADAPT) | chronic lower back pain / degenerative disc disease | cell therapy | Phase 1 |
| CELZ-201 (CREATE-1) | new-onset Type 1 diabetes | cell therapy | Phase 1 |
| Ultrasome | knee osteoarthritis | biologic-other | Pre-clinical |
| ImmCelz (CELZ-100) | Type 1 diabetes / heart disease | cell therapy | Pre-clinical |
| iPScelz | degenerative diseases | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.